The Central Discipline Inspection Commission commented on the Xiangya incident; innovative consumables can enter medical insurance; AIDS new drugs only need to be used twice a year

Big events in the medical industry have aroused social attention.

On August 23, the World Health Organization announced that China has passed a new round of evaluation through the national regulatory system of vaccine. The Liu Xiangfeng incident in the second hospital of Xiangya, bluntly stated, "Why did not find it early and resolved early."

At the market level, the disclosure of the half-year report of the pharmaceutical company continued: Jingdong's health reached 20.2 billion yuan in the first half of the year, a year-on-year increase of nearly 50%; The product's sales in 2021; "Medical Beauty Lifa" Aesthetic Customer Net earning 591 million yuan, an increase of 38.9%year -on -year.

The Jianzhi Bureau organizes more information as follows:

Heavy policy

1. The Central Discipline Inspection Commission commented on the incident of the Second Hospital of Xiangya

This week, Liu Xiangfeng, the Second Hospital of Xiangya, Hunan, made new progress. According to the official website of Xiangya Second Hospital, on August 25, the Changsha Municipal Supervision Committee of Hunan reported that the incident stated that Liu Xiangfeng was "suspected of serious violations and is currently undergoing supervision and investigation." On the same day, Xiangya Second Hospital held a special operation of "Improve Medical Style · Standardize Medical Acts" to implement a "one -vote veto" system for medical ethics.

On August 28, the website of the Central Commission for Discipline Inspection issued a document to comment on the Liu Xiangfeng incident that it would be reflected from the Liu Xiangfeng incident: "Why did not settle early internally and early? Is the daily supervision and management powerful and in place? "

2. The State Medical Insurance Bureau supports innovative consumables into medical insurance

On August 24, when the National Medical Insurance Bureau resumed the "further promoting the market access of innovative medical device products" by the Fifth Session of the Fifth Session of the 13th National People's Congress No. 8013, it would promote the establishment of a "nationwide in the country and consumables for medical equipment and consumables. The unified hanging network and trading rules "at the same time leave a certain market in addition to the purchase of volume to provide space for innovative products to develop the market.

In addition, the National Medical Insurance Bureau is improving relevant policies to guide various places to "timely incorporate qualified innovative medical consumables in the scope of medical insurance payment in accordance with procedures."

3. Cardiac intervention electrical physiological consumables will be collected

On August 26, the Fujian Provincial Medical Insurance Bureau issued a draft of solicitation of comments stating that the inter -provincial alliance of provincial alliances that will soon start the heart intervention of electrical physiological medical consumables. According to regulations, relevant opinions or suggestions must be feedback before September 2 this year.

According to the plan of Fujian Province, this collection of 11 cardiac interventional electro -interventional electrical consumables, including the room spike sheath, electrical catheter sheath, and room septum assassination needle. The procurement cycle is 2 years.

Industry affairs

1. Listed pharmaceutical companies have been fined 300 million funds

On August 23, Guangdong Tai'antang Pharmaceutical announced that the company and the controlling shareholder Tai'antang Group Co., Ltd. received a "Administrative Regulatory Measures Decision" issued by the Guangdong Securities Regulatory Bureau.

The "Decision" shows that during the period of 2019-2021, Tai'antang Group has accumulated a total of 328 million yuan of funds for listed companies. As of the end of 2021, 251 million yuan has not been returned to the listed company. In addition, since the company did not disclose the 2021 annual report within the statutory period, the CSRC has now decided to conduct a investigation of the company.

2. Sichuan: The annual diagnosis and treatment of traditional Chinese medicines will be 210 million people

On August 22, the Sichuan Provincial Government issued the "Implementation Plan for the Construction of the Comprehensive Reform Reform Reform of Sichuan Province" and stated that it deployed the development of the Chinese medicine industry in the province.

The "Plan" states that as of 2025, the province's annual diagnosis and treatment of traditional Chinese medicine in the province will reach 210 million; to cultivate 2 large varieties of Chinese medicinal materials with an annual output value of over 5 billion yuan, more than 3 or more of reaching 2 billion yuan. The comprehensive output value of Chinese medicinal materials reached 150 billion yuan. In addition, in terms of the cultivation of human -oriented, the high -level talents of traditional Chinese medicine in the province in 2025 needed an increase of 40%to 15,000.

3. Amazon shut down remote medical business

On August 24th, according to foreign media reports, Amazon will close its long -range medical business Amazon Care before the end of the year because the business "failed to provide sufficient valuable services for Amazon's target customer group." Neil Lindsay, the head of Amazon Health Services, said that this was a decision made by "a few months" because it did not meet the company's "long -term plan".

Amazon launched the Amazon Care business in 2019, which mainly provides online medical consultation. In addition, you can arrange professional medical care personnel to go to the patient's home or office to follow up.

New drug inventory

1. 1.7 billion in Hansen Pharmaceuticals introduced new crown oral medicine

On August 22, Hansen Pharmaceutical announced that with the price of 12 million head payments and a potential milestone of 1.68 billion yuan, the new crown drug GDI4405 of the Beijing Huayi Health Drug Research Center GDI4405 Essence

GDI4405 is a oral small molecular 3-CL protease inhibitor. It shows strong antiviral activity for mutant strains such as Delta and Omikon. Beijing Huayi Health Drug Research Center launched the research and development of this product in early 2020.

2. Geely HIV long -acting medicine is approved in the EU

On August 22, Geelyd announced that the European Commission had awarded its HIV drug Sunlenca injection and tablets of listing, and combined with other anti -reverse virus drugs for adult patients with multiple resistance HIV infections.At present, Sunlenca is also the only HIV treatment drug in the world that only needs to be administered twice a year.3. The first A -type hemophilia gene therapy was approved for listing by the European Union

On August 24th, Biomarin Pharmaceutical announced that the European Commission approved its gene therapy ROCTAVIAN to be able to go public for the treatment to treat the severe coagulation factors VIII inhibitors and adenocyrilic virus 5 (AAV5) antibodies.Essence

It is worth mentioning that this is the world's first gene therapy for type A hemophilia.The European Commission also awarded the therapy orphan medicine that ROCTAVIAN will obtain a market exclusive period in the next 10 years.

Writing | Guyue

Edit ｜ Jiang Yun Jia Ting

Operation | Valley

Illustration | Visual China

####

- END -